{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:06:16Z","timestamp":1787742376176,"version":"build-2784847793"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Treating severe pneumonia caused by multiple pathogens in immunocompromised hosts (ICHs) presents significant challenges. Isavuconazole (ISA), a next-generation triazole antifungal agent, has shown promise in managing fungal infections. However, clinical evidence regarding its efficacy in cases of complex infections involving multiple pathogens in ICHs remains limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>This study describes a case series of three ICHs diagnosed with severe pneumonia, including invasive aspergillosis (IA). All three patients received ISA-based personalized antimicrobial regimens. Alleviation of symptoms was observed in all patients following antimicrobial treatment, with notable absorption of pulmonary lesions and no significant hepatorenal toxic side effects, with no recurrence observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ICHs are highly susceptible to fungal infections, and the severity of their condition can escalate dramatically, with a significant risk of mortality, when severe pneumonia caused by multiple pathogens occurs concurrently. A stepwise treatment strategy, which balances the use between immunosuppressant and effective antimicrobial treatment, is crucial. The selection of appropriate drugs should account for potential adverse drug reactions (ADRs). In this case series, ISA exhibited robust efficacy in treating IA with minimal ADRs. Therefore, ISA represents a valuable option for managing severe pneumonia in ICHs, particularly in the context of IA and co-infections caused by multiple pathogens.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1565071","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:13:41Z","timestamp":1745813621000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Isavuconazole as an optimal treatment option for multiple pathogens induced severe pneumonia in immunocompromised hosts: a case series report"],"prefix":"10.3389","volume":"12","author":[{"given":"Xinyin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjing","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxiang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1513\/AnnalsATS.202212-1019ST","article-title":"Immunocompromised host pneumonia: Definitions and diagnostic criteria: An official American thoracic society workshop report.","volume":"20","author":"Cheng","year":"2023","journal-title":"Ann Am Thorac Soc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/01.JAA.0000694948.01963.f4","article-title":"Infectious disease considerations in immunocompromised patients.","volume":"33","author":"McGrath","year":"2020","journal-title":"JAAPA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00134-019-05906-5","article-title":"Diagnosis of severe respiratory infections in immunocompromised patients.","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/MCP.0000000000000051","article-title":"Pneumonia in the immunocompromised host.","volume":"20","author":"Letourneau","year":"2014","journal-title":"Curr Opin Pulm Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/jof4030098","article-title":"Treatment of Aspergillosis.","volume":"4","author":"Jenks","year":"2018","journal-title":"J Fungi."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New perspectives on antimicrobial agents: Isavuconazole.","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"key":"B7","year":"2022","journal-title":"WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action."},{"key":"B8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1055\/s-0031-1295715","article-title":"Pulmonary aspergillosis: Recent advances.","volume":"32","author":"Thompson","year":"2011","journal-title":"Semin Respir Crit Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1086\/513943","article-title":"Invasive aspergillosis.","volume":"26","author":"Denning","year":"1998","journal-title":"Clin Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cmi.2024.08.006","article-title":"Invasive fungal disease in the immunocompromised host: Changing epidemiology, new antifungal therapies, and management challenges.","volume":"31","author":"Giannella","year":"2025","journal-title":"Clin Microbiol Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/cid\/ciaa863","article-title":"COVID-19 in immunocompromised hosts: What we know so far.","volume":"72","author":"Fung","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S0140-6736(05)67381-3","article-title":"Advances and challenges in management of invasive mycoses.","volume":"366","author":"Patterson","year":"2005","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline.","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s15010-013-0539-3","article-title":"SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients.","volume":"42","author":"Montagna","year":"2014","journal-title":"Infection."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: The SAIF network (2005-2007).","volume":"17","author":"Lortholary","year":"2011","journal-title":"Clin Microbiol Infect."},{"key":"B16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.bbmt.2018.09.028","article-title":"Mainly post-transplant factors are associated with invasive aspergillosis after allogeneic stem cell transplantation: A study from the surveillance des aspergilloses invasives en france and soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire.","volume":"25","author":"Robin","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s40121-021-00486-8","article-title":"Epidemiology and incidence of COVID-19-associated pulmonary aspergillosis (CAPA) in a Greek tertiary care academic reference hospital.","volume":"10","author":"Paramythiotou","year":"2021","journal-title":"Infect Dis Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"11845","DOI":"10.3389\/ti.2023.11845","article-title":"Isavuconazole for treating invasive mould disease in solid organ transplant recipients.","volume":"36","author":"Silva","year":"2023","journal-title":"Transpl Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"864163","DOI":"10.3389\/fcimb.2022.864163","article-title":"Editorial: mNGS for fungal pulmonary infection diagnostics.","volume":"12","author":"Li","year":"2022","journal-title":"Front Cell Infect Microbiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"100400","DOI":"10.1016\/j.lanepe.2022.100400","article-title":"Evolving epidemiology of pneumocystis pneumonia: Findings from a longitudinal population-based study and a retrospective multi-center study in Germany.","volume":"18","author":"Kolbrink","year":"2022","journal-title":"Lancet Reg Health Eur."},{"key":"B21","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3390\/jof9080812","article-title":"Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection.","volume":"9","author":"Xue","year":"2023","journal-title":"J Fungi."},{"key":"B22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1055\/s-0040-1708816","article-title":"Nocardia spp.: A rare cause of pneumonia globally.","volume":"41","author":"Lynch","year":"2020","journal-title":"Semin Respir Crit Care Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/infdis\/jiac020","article-title":"Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalization.","volume":"226","author":"Alanio","year":"2022","journal-title":"J Infect Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.5582\/bst.2021.01279","article-title":"Cytomegalovirus viremia is associated with poor outcomes in AIDS patients with disseminated nontuberculous mycobacterial disease.","volume":"15","author":"Tian","year":"2022","journal-title":"Biosci Trends."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41598-017-01818-w","article-title":"Risk factors for Pneumocystis jirovecii pneumonia (PJP) in kidney transplantation recipients.","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","article-title":"The clinical spectrum of pulmonary aspergillosis.","volume":"70","author":"Kosmidis","year":"2015","journal-title":"Thorax."},{"key":"B27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12929-020-00667-6","article-title":"Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment.","volume":"27","author":"Gopalaswamy","year":"2020","journal-title":"J Biomed Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1128\/AAC.00101-17","article-title":"Impact of mucositis on absorption and systemic drug exposure of isavuconazole.","volume":"61","author":"Kovanda","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.","volume":"54","author":"Schmitt-Hoffmann","year":"2016","journal-title":"Int J Clin Pharmacol Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e01292-17","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats.","volume":"61","author":"Schmitt-Hoffmann","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents.","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/mmy\/myy052","article-title":"Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?","volume":"57","author":"Jenks","year":"2019","journal-title":"Med Mycol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1128\/AAC.00251-13","article-title":"Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.","volume":"57","author":"Hoenigl","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients.","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection."},{"key":"B36","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial.","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet."},{"key":"B37","author":"Kontoyiannis","year":"2014","journal-title":"1211 A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients. Open Forum Infectious Diseases."},{"key":"B38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3111\/13696998.2016.1164175","article-title":"Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.","volume":"19","author":"Horn","year":"2016","journal-title":"J Med Econ."},{"key":"B39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica."},{"key":"B40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive summary: Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3390\/microorganisms11092229","article-title":"Real-world, multicenter case series of patients treated with isavuconazole for invasive fungal disease in China.","volume":"11","author":"Wu","year":"2023","journal-title":"Microorganisms."},{"key":"B42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/myc.12885","article-title":"Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.","volume":"62","author":"Bongomin","year":"2019","journal-title":"Mycoses."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12879-024-09031-7","article-title":"A regimen based on the combination of trimethoprim\/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: A retrospective study in a tertiary hospital.","volume":"24","author":"Li","year":"2024","journal-title":"BMC Infect Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12879-019-3683-2","article-title":"Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.","volume":"19","author":"Floros","year":"2019","journal-title":"BMC Infect Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/13696998.2019.1638789","article-title":"The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.","volume":"23","author":"Floros","year":"2020","journal-title":"J Med Econ."},{"key":"B47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","article-title":"Cost-effectiveness analysis of isavuconazole vs. Voriconazole as first-line treatment for invasive aspergillosis.","volume":"34","author":"Harrington","year":"2017","journal-title":"Adv Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1565071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:13:42Z","timestamp":1745813622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1565071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":47,"alternative-id":["10.3389\/fmed.2025.1565071"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1565071","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"article-number":"1565071"}}